Tyra Biosciences Inc - Asset Resilience Ratio
Tyra Biosciences Inc (TYRA) has an Asset Resilience Ratio of 63.20% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TYRA liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Tyra Biosciences Inc's Asset Resilience Ratio has changed over time. See how many days can Tyra Biosciences Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Tyra Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TYRA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $178.62 Million | 63.2% |
| Total Liquid Assets | $178.62 Million | 63.20% |
Asset Resilience Insights
- Very High Liquidity: Tyra Biosciences Inc maintains exceptional liquid asset reserves at 63.20% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tyra Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Tyra Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020 |
Biotechnology | 63.76% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 29.87% |
Annual Asset Resilience Ratio for Tyra Biosciences Inc (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Tyra Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 63.20% | $178.62 Million | $282.61 Million | -5.42pp |
| 2024-12-31 | 68.62% | $249.47 Million | $363.56 Million | +4.22pp |
| 2023-12-31 | 64.40% | $145.46 Million | $225.86 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $266.18 Million | -- |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more